Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ) just unveiled an update.
AstraZeneca Pharma India Limited has obtained permission from the Central Drugs Standard Control Organization (CDSCO) to import and distribute Datopotamab Deruxtecan powder for infusion (brand name: Datverzo) in India. This new drug targets unresectable or metastatic HR-positive, HER2-negative breast cancer and has been approved for patients undergoing prior endocrine therapy and chemotherapy for such conditions. The approval marks a significant advancement, enabling marketing efforts for Datverzo in this critical oncology segment, subject to additional regulatory clearances. This announcement strengthens AstraZeneca’s position in the oncology market while underlining its commitment to advancing treatment options for severe medical conditions in India.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of innovative drugs. The company provides treatments for various medical conditions, particularly in oncology, cardiovascular, and metabolic disorders.
Average Trading Volume: 638
Technical Sentiment Signal: Strong Buy
Current Market Cap: 225.3B INR
Find detailed analytics on ASTRAZEN stock on TipRanks’ Stock Analysis page.